Press Releases

Press Releases

Date Title
5/6/21 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
4/22/21 Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
4/21/21 Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
4/15/21 GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
4/8/21 Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
4/6/21 Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
4/5/21 Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant
3/29/21 Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
3/26/21 GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
3/10/21 Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
Displaying 11 - 20 of 31